Page 12 - Indian Pharma Companies

Three key reasons why CLSA is bullish on pharma MNCs in India

MNC stocks have outperformed local peers for the first time in over a decade and have also significantly outperformed the Nifty over the last 18 months.

Indian pharmaceutical companies spread business to avoid regulatory ire

Increased USFDA import alerts could be reason for finding alternative sites

FDA observations on Telangana plant a fresh headache for Aurobindo Pharma

The Telangana unit in question is an important one contributing about a fifth to US revenues

USFDA impact: DCGI asks states told to put antacids under scanner

The ranitidine market in India is roughly around Rs 700 crore, with about 180 brands

S&P revises Glenmark outlook to 'negative' on weak operating performance

Glenmark's capex for the first quarter of fiscal 2020 was Rs 190 crore, in line with its guidance

China's new drug law may open door for Indian generic medicines: Report

India has been demanding that China open its pharmaceutical market to Indian drugs as part of the efforts to lower the $57 billion trade deficit

300 fresh pharma unit applications up for approval in Gujarat: FDCA

As per the state FDCA commissioner, the state has benefited from the introduction of GST

Aurobindo Q1 profit up 39.5% at Rs 636 crore on strong revenue growth

Revenue from operations rose 28.1% year-on-year to Rs 5,444.6 crore during the quarter under review

India's new drug nods from US dip in Q1 due to increased scrutiny on firms

India's share of ANDA approvals given by the US Food and Drug Administration (USFDA), too, has fallen from 43 per cent in fourth quarter (Q4) of 2018-19 (FY19) to 33 per cent in Q1FY20

Pharma funds remain in poor health amid headwinds on compliance

The BSE Healthcare Index has fallen 10 per cent in the last one year

What's bugging Indian, Chinese medicine companies making crucial heart drug

US inspectors cite Cadila Healthcare and Alkem Laboratories--both makers of valsartan--for quality-control failures.

Charticle: How Jan Aushadhi stores are disrupting the Indian pharma market

Analysts point out that growth from product introductions has nearly halved over the last two years as the drug regulator has been more stringent about new combination drugs

Jan Aushadhi scheme may disrupt 20% of Indian pharma market sales: Report

India has over 5,000 Jan Aushadhi stores that cover a list of 800 plus drugs, both chronic and acute

Cold wave across US to bring big business for Indian drug companies

There have been 20.4 million to 23.6 million flu illnesses in the US between October 1, 2018, and February 23, 2019

Indian pharma to hit double-digit growth on US sales, weak rupee: CRISIL

As per Crisil, green shoots are already visible in the first quarter for 20 of these listed drug-makers

Warning letters to Indian pharma companies from US FDA declining: Study

The number of cases of data integrity violations too is showing a decline, says study by IPA and consultancy firm McKinsey

Indian pharma sees traction in novel biologics

While Glenmark is betting on its biologic for atorpic dermatitis, Biocon was the first to develop and introduce two novel biologics in the Indian market

Competition takes shine off niche pharma products

Aurobindo has been able to partially buck the trend; analysts expect prospects of most players to improve in second half of FY19